Please assess the completion status of the following clinical trial:

Trial Title: DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized with moderate, severe, or early critical COVID-19 illness diagnosed by RT- PCR~* Acute liver injury (including acute on chronic liver disease) or acute kidney injury or moderate COVID-19 pneumonia~Exclusion Criteria:~* Critical COVID-19 illness (MAP \< 60 mm Hg, on mechanical ventilator for ≥ 5 days)~* On maintenance hemodialysis or peritoneal dialysis~* Child Pugh C cirrhosis~* Hepatorenal syndrome~* Ascites and/or hepatic encephalopathy~* History of end stage renal disease or CKD with eGFR \< 15 mL/min/1.73m2~* Women who are pregnant or breast feeding~* Receipt of other concomitant experimental therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DUR-928 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).